In the News

28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy

In the News
Spotlights
Case Studies

In the News

June 9, 2025
4
min read
The Clumps of Brain Cells That Can Play Pac-Man
What they mean for medicine and perhaps the future of AI data centers.
March 23, 2026
3
min read
28bio’s Endurance Study Meets Primary Endpoint, Showing CNS-3D Brain Organoids Predict Clinical Seizure Liability
28bio reports Endurance Study results showing brain organoids predict clinical seizure liability with 83% sensitivity and 89% specificity.
April 2, 2026
5
min read
Accelerating Organoid Adoption Set to Transform Cancer Drugs
When asked about the biggest obstacles preventing organoids from reaching their full potential, Alif Saleh, CEO of 28bio, emphasizes that adoption, not technology, is the primary hurdle, particularly in drug discovery, where a staggering 95% failure rate is accepted as the norm.
More News
Arrow Down Icon
Spotlight

28bioGRANT for Neurodegenerative Disease Awardees Announced

28bio announces the 2026 recipients of the 28bioGRANT for Neurodegenerative Disease, supporting innovative research in CNS-targeted nanotherapeutics and human iPSC-based Alzheimer’s disease modeling.

Spotlights

February 5, 2026
7
min read
Modeling Myelination and Therapeutic Response in Demyelinating Disorders
CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.
February 5, 2026
5
min read
Organoid Intelligence Offers New Evidence of Learning-related Activity in Human Neural Tissue
Human-derived neural networks can exhibit measurable markers of learning and memory processes.
December 5, 2025
7
min read
Organoid Neurotoxicity Testing Embraced by FDA and NIH
Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.

Subscribe to 28bioNEWS

28bioNEWS is a monthly market intelligence briefing built for those shaping the future of drug discovery and development.
Learn More
Spotlight

Modeling Myelination and Therapeutic Response in Demyelinating Disorders

CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.

Case Studies

Case Study
5
min read
Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment
CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Takeda’s Validated Method for CNS Safety

Learn how CNS-3D brain organoids deliver 7.4× better clinical predictivity than animal models in this on-demand webinar with Takeda’s Investigative Toxicology team.
Learn More
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy